- Tags: inherited retinal disease
Pipeline
Kiora's KIO-104 receives US patent for expanded protection of inflammatory retinal diseases
The investigational small molecule’s intellectual property and potential market exclusivity are now protected through 2043.
Pipeline
Boehringer partners with Re-Vana on extended-release ophthalmic therapeutics
Collaboration involves photo-crosslinked, biodegradable implants designed to enable continuous, 3-to-12-month drug delivery to treat retinal diseases.
Research
Eye2Gene study supports AI analysis of SPECTRALIS platform for IRDs
New research evaluates the use of a deep learning algorithm trained on retinal scans to identify IRD-causing genes and predict patients’ inherited retinal disease.
Pipeline
FDA OKs AAVantgarde's IND for Stargardt gene therapy trial
Clearance enables initiation of FIH study on AAVB-039, an AAV8 that delivers the full-length ABCA4 gene to address the disease’s root cause—enabling treatment for all types.
Research
New IRD genetic testing maps mutations to improve diagnoses
Newly identified gene variants may enhance speed and accuracy in diagnosing inherited retinal diseases.
Products
Zeiss debuts new research data platform for integrated workflows
Company’s cloud-based solution uses AI technology to integrate accessible clinical and research data into clinicians’ daily routines.
Business
Foundation Fighting Blindness appoints new chief scientific officer
Amy Laster, PhD, is spearheading the organization’s 5-year strategic plan as the organization plans to host a free IRD-based webinar on March 13.
Business
Bausch + Lomb may be acquiring InflammX Therapeutics
Option agreement indicates B+L intends to purchase the biotech company and its orally-administered therapeutic under clinical investigation for retinal diseases.
Pipeline
Nona Biosciences and Kodak Sciences to advance antibody therapies for ophthalmic diseases
Kodiak to further develop retinal disease asserts via Nona’s Harbour Mice platform, designed to generate fully human monoclonal antibodies at half the size of regular IgG.
Pipeline
Alkeus receives two rare disease FDA designations for Stargardt candidate
New statuses join gildeuretinol’s (ALK-001) previous Fast Track and Orphan Drug designations; gives company potential eligibility for priority review voucher.
Business
Ocuphire Pharma just purchased Opus Genetics
Operating under the name “Opus Genetics,” the combined company features a pipeline of IRD-targeted gene therapy candidates.
Events
Foundation Fighting Blindness to host webinar on IRDs, low vision
Free virtual event for ECPs features a case study approach for guiding newly diagnosed patients through treatment and care.
Events
Eyes On Retina 2024 features hot topics and global attendees
Largest virtual retina event of the year clocks in over 2.4K clinician viewers from 75 countries.
Pipeline
FDA grants IND clearance for BlueRock's primary photoreceptor disease cell therapy
New status paves the way for a phase 1/2a trial to evaluate the safety and efficacy of an induced pluripotent cell-derived candidate.
Events
KOLs eye the future of genetic engineering and cell transplantation
Industry leaders from four leading ophthalmic companies debut the latest clinical developments in cell-based therapeutics.Events
Registration opens for Eyes On Retina 2024
This year’s largest virtual retina event of the year kicks off in September.
Pipeline
Beacon Therapeutics to evaluate patented AAV gene therapy for retinal diseases
Licensing agreement involves potential development and commercialization of Abeona Therapeutics’ patented capsid, a pan-retinal-administered vector.
Research
Preventing certain light exposure may decrease IRD risk
First study of human subjects investigates IRD risk and light exposure.
Pipeline
Neurotech Pharma earns BLA priority review for MacTel cell therapy
Investigational ocular implant is designed to slow progression of gradual central vision deterioration in rare neurodegenerative retinal disease.
Research